Related references
Note: Only part of the references are listed.Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis
Dean Seah et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
Rajiv A. Perinbasekar et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease
Sine Buhl et al.
INFLAMMATORY BOWEL DISEASES (2017)
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Review article: dose optimisation of infliximab for acute severe ulcerative colitis
P. Hindryckx et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
A. J. Yarur et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience
T. Billiet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
B. Ungar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Standardisation of Study Protocols - Pros and Cons
Geert D'Haens
JOURNAL OF CROHNS & COLITIS (2016)
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
David J. Gibson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?
Niels Vande Casteele et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
Ulcerative Colitis Care Pathway
Themistocles Dassopoulos et al.
GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
1071 Development and Validation of a Novel Enterography-Based Stricture Severity Score (SSS) to Predict the Need for Surgery in Patients With Stricturing Crohn's Disease
Sansrita Nepal et al.
GASTROENTEROLOGY (2015)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin et al.
GASTROENTEROLOGY (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Crohn's Disease Evaluation and Treatment: Clinical Decision Tool
William J. Sandborn
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn's disease
Jeremy Adler et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
Trine Olsen et al.
CYTOKINE (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas
DA Schwartz et al.
INFLAMMATORY BOWEL DISEASES (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement
M Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)
Share Paper
